HHS Will Let Pharmacies Compound BPC-157 and Five Other Peptides, With Conditions

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) said it would stop enforcing part of federal drug law for six peptides. The six are BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. Under the new policy, HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" that compounds a drug from one of them. The Federal Register notice is signed by Health Secretary Robert F. Kennedy Jr. It was filed on October 28 and published on October 30.

The policy makes these peptides easier to get through a doctor and a licensed pharmacy. It does not make them FDA-approved, however, and it does not show that they work. HHS's own statement, quoted by ABC News, says the policy "does not grant FDA approval or establish clinical safety and effectiveness." It is also temporary, since HHS can pull it back, in whole or in part, if a safety or quality problem appears.

This guide covers what the policy allows, who it covers, the conditions pharmacies must meet, and what is still unknown about the peptides themselves.

A few terms explain most of the policy.

Compounding is when a pharmacist or doctor mixes a drug for one patient. As the HHS notice itself says, compounded drugs are not FDA-approved, which means the FDA does not review their safety, effectiveness, or quality before they are sold.

503A pharmacies are traditional pharmacies, licensed by their state, that compound drugs for individual patients with a prescription. The name comes from Section 503A of the Federal Food, Drug, and Cosmetic Act.

503B outsourcing facilities are larger operations that make compounded drugs in bulk. They register with the FDA and follow stricter manufacturing rules, and NPR reported that the new policy does not cover them.

The 503A bulks list is the FDA's list of raw ingredients that 503A pharmacies may use when the ingredient is not part of an approved drug. None of the six peptides is on it, and adding a substance takes a formal rule, with a proposal, public comments, and a final decision. The Associated Press reported in mid-October that this process "could take years."

Enforcement discretion fills that gap. The law stays the same, but HHS says it will not act against pharmacies that compound these peptides under its conditions while the FDA works on the list. The notice says the policy "does not establish any rights for any person and is not binding on HHS or the public." In practice, that means it can change without a new rule.

In 2023, the FDA placed BPC-157 and more than a dozen other injectable peptides on a list of substances it considered too risky to compound. The Associated Press reported that the agency's concerns included contamination, allergic reactions, and tumor growth. Much of the demand then moved to online sellers of "research use only" vials.

Earlier in 2026, Kennedy directed the FDA to reconsider a short list of these widely promoted peptides. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC), an outside panel, voted to recommend six of the seven peptides it reviewed for the bulks list. It voted against the seventh, emideltide, also called DSIP. Several votes were close; BPC-157 passed 8 to 6 with one abstention. Our vote breakdown has each tally.

The FDA's own scientists had reached the opposite conclusion. Their briefing documents said there was not enough evidence to support any of the seven, pointing to thin human data, immune reactions, and contamination found in product samples. Our briefing summary walks through each peptide. NBC News reported that several panel members had ties to the peptide industry or to a lawmaker who has pushed for wider access.

The nominations were for specific medical uses. As NPR summarized them, BPC-157 was proposed for ulcerative colitis, epitalon for insomnia, KPV and TB-500 for wound healing, MOTS-c for metabolic health, and semax for migraine. Online marketing reaches much further. BioSpace noted that BPC-157 and TB-500 are sold together as the "Wolverine stack" for muscle building and soft-tissue repair.

HHS sent an "interim access policy" to the White House budget office for review on October 14. Two weeks later, HHS released the policy itself, which its Federal Register notice describes as both interim and a draft.

The Federal Register notice names three groups: state-licensed pharmacies, federal facilities, and licensed physicians. The detailed conditions sit in an appendix on the HHS website. We could not access that document directly, so the conditions below come from news reports and a trade group summary.

According to the American Med Spa Association's summary of the policy, compounders must:

• Source the peptide from an FDA-registered manufacturer that follows current good manufacturing practice (CGMP) rules.
• Get certificates of analysis covering identity, purity, potency, and contaminants.
• Use only a single listed active ingredient in each product, which rules out blends.
• Meet labeling and delivery-device requirements.
• Compound only under a valid prescription for a specific patient.
• Report serious adverse events and product-quality problems.

NBC News reported similar terms: pharmacies must certify the identity and purity of the compounds and report side effects. HHS's statement to ABC News listed "patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting."

Two limits matter for patients. First, a prescription is required, so the policy does not cover sales to people without one. Second, according to the AmSpa summary, the single-ingredient rule means popular multi-peptide blends fall outside it. The trade group also warned its members not to treat the policy as "a blanket authorization to prescribe, dispense or administer these peptides."

Compounding groups welcomed the move. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told NPR the policy is a "more accountable alternative" for people now buying gray-market peptides. He said it brings them into a system with "pharmacy standards, regulatory oversight, and serious adverse event reporting." The American Academy of Peptide Medicine called it "a vital step toward eliminating the unsafe gray and black markets," BioSpace reported. HHS said the goal is to "advance patient choice and freedom while appropriately protecting patient safety."

Critics focused on the evidence and on how the decision was made. Dr. Robert Steinbrook of Public Citizen said, "Kennedy has undermined the FDA and threatened public health." He told NPR that peptides should go through the standard approval process for new drugs. Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest, told NBC News that the FDA was "turning a blind eye." PhRMA general counsel Jim Stansel said access to peptides that have not been shown safe or effective in clinical trials "jeopardizes patient safety."

The Partnership for Safe Medicines went further. The week before the policy came out, it filed a citizen petition urging the FDA to ignore its advisory committee's July recommendation. The trade group RAPS reported that the petition argues compounding these peptides is illegal and poses safety risks. Its executive director, Shabbir Imber Safdar, said the policy "leaves Americans in a gray area as to whether peptides are safe or not."

Probably not right away. Joshua Fritzler is president of Olympia and Wesley Pharmaceuticals in central Florida. He told NPR, "We won't be able to meet demand." His company will likely compound only one of the six peptides, and it has to prepare its facility first. "I don't think all the [503]As in the country could meet the demand," he said.

Brunner also warned about delays. Ingredient suppliers and pharmacies must first verify that the active ingredients meet the policy's terms. Because 503B outsourcing facilities are left out, the large-scale producers that make many other compounded drugs cannot help fill the gap.

For patients, this means early supply is likely to be limited, and a pharmacy may offer only one or two of the six peptides.

The policy does not legalize the online "research use only" market. Those sellers label vials as lab chemicals "not for human consumption" while marketing them for people. The FDA treats such products as unapproved drugs, as our guide to the label explains. Nothing in the new policy changes that.

The practical difference is accountability. A pharmacy working under the policy must buy from a registered manufacturer, test each ingredient, fill a named patient's prescription, and report serious side effects. A research-chemical seller has none of those duties. Lab testing of gray-market peptides has repeatedly found wrong doses and contamination, as we covered in Peptide Quality Problems in 2026.

The policy does not make every pharmacy careful, though. If you get a prescription, it is still worth asking the pharmacy who made the ingredient and whether you can see a certificate of analysis. Our guide to evaluating a compounding pharmacy lists the questions to ask.

Several things could narrow or end it.

A safety or quality signal. The notice says HHS "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises." The adverse event reports pharmacies must file are the most likely source of that signal.

Public comments. Comments are open on regulations.gov under docket HHS-OASH-2026-0496 through November 13. The next section explains how to send one.

The FDA's final rules. The policy is meant to last while the FDA decides through rulemaking whether to add each peptide to the bulks list. The notice says future rules "may propose adding some or all of these peptides." If the FDA declines to list a peptide, the reason for the policy goes away.

Legal and political pressure. The Partnership for Safe Medicines petition is pending. Because the policy is not binding, HHS could also withdraw it later without a new rule.

The notice appeared in the Federal Register on October 30, 2026, as document 2026-22192. It accepts written comments for two weeks after that date. CBS News reported that the comment period runs through November 13.

The notice says written comments go through regulations.gov under docket HHS-OASH-2026-0496. To find it, search for that docket number on the site. Comments can support the policy, oppose it, or ask for changes.

Specific comments are easier for an agency to use than general statements of support or opposition. Examples include a side effect or quality problem you had with one of these peptides, how you got the product, what a pharmacy could or could not supply, or a published study with its citation. HHS has not said how it will weigh the comments or when it will respond.

The notice lists Victoria Marshall at the HHS Office of the Assistant Secretary for Health as the contact for questions.

The policy changes access, not evidence. ABC News reported that there are no published clinical trials showing these specific peptides are effective in humans for any condition. Most of the research on BPC-157, TB-500, KPV, and MOTS-c comes from animals and cell studies. Semax has older Russian clinical studies, which FDA staff described as small and mostly unblinded. Our evidence gap review lays out what exists for each.

Safety data are thin too: BioSpace noted that the FDA's 2023 concerns included the risk of immune reactions, and the agency's 2026 briefing documents raised them again. The new reporting requirement could, over time, produce better information about side effects than the gray market ever did. Until then, anyone using these peptides is relying on limited and mostly indirect data.

For profiles of individual compounds, see peptidelist.org's pages on BPC-157, TB-500, KPV, MOTS-c, and semax.

• Is the pharmacy state-licensed and compounding under 503A? The policy covers those pharmacies, not 503B facilities or online research sellers.
• Who made the peptide ingredient? The policy calls for an FDA-registered manufacturer that follows CGMP rules.
• Can I see the certificate of analysis? It should cover identity, purity, potency, and contaminants.
• Is this a single peptide? Blends fall outside the policy, according to the AmSpa summary.
• What is the medical reason? The evidence differs by peptide and by condition, and the nominated uses are narrower than most marketing.
• What side effects should I report, and to whom? Pharmacies must report serious adverse events. Tell your prescriber about any reaction.

None of these questions makes an unproven treatment proven. They help you avoid the worst-quality products while the evidence catches up.

Update (October 31, 2026): HHS published the policy in the Federal Register on October 30, 2026. We changed references to a scheduled publication date, gave the comment deadline as November 13 rather than about November 13, and added a section on how to comment.